Reimagining the Translation from Biologics Discovery to Development

Life Sciences, Drug Discovery & Development, Preclinical,
  • Tuesday, May 07, 2024

Traditionally, the journey from biologics discovery to their development and initial human trials has followed a familiar route, sticking to established norms. It is now more vital than ever for biologics developers to obtain access to the most effective tools, technologies and machine learning strategies to mitigate hurdles during the scaling-up process.

In this webinar, the expert speakers will discuss the combined use of an open-source platform and hybrid–mechanistic process model that was developed using data sets from both stable bulk cultures (SBCs) and derivative clones using cell line technologies. This helps enable well-controlled SBCs, high titers, process robustness, scalability and speed-to-clinic.

The attendees will also learn about using SBC-based platforms, enabling companies to reduce the cost/time cycle of early development. They will also understand the importance of better alignment between biotechs and service providers (such as CROs and CDMOs) to effectively bridge the translation from preclinical to clinical development.

Register for this webinar today to gain insights into the most effective tools, technologies and strategies for biologics discovery and development.


Brian R. Berquist, PhD, Chief Development Officer, Wheeler Bio, Inc.

Dr. Brian R. Berquist, with over 20 years of experience spanning industry, government and academia serves as the Senior Vice President and Chief Development Officer at Wheeler Bio. In this role, he leads the Cell Line, Process, Analytical and Formulation Development departments, driving innovation and excellence in biopharmaceutical development.

Prior to joining Wheeler Bio, Dr. Berquist held progressive roles at Caliber Biotherapeutics and iBio CDMO, initiating at the bench as a downstream process development scientist and commencing as the Vice President of Process Development and Head of Platform Technology Development. During his tenure, he spearheaded the establishment of process development, analytical characterization and technology transfer teams, advancing therapeutics and vaccines for both internal programs and CDMO services clients. He also played a pivotal role in enhancing upstream and downstream technologies.

He holds a BS in Biochemistry and Molecular Biology from the University of Massachusetts and a PhD in Molecular Medicine from the University of Maryland School of Medicine, graduating summa cum laude. Following this, he completed a post-doctoral fellowship at the Laboratory of Molecular Gerontology at the National Institute on Aging, part of the National Institutes of Health.

With his extensive background and expertise, Dr. Berquist is dedicated to driving advancements in biopharmaceutical development, ensuring the delivery of innovative therapies to improve global health.


Message Presenter

Oren Beske, PhD, Amalgamator of Business and Biology, ATUM

Dr. Oren Beske joined ATUM in 2019 and brings nearly 20 years of industry experience to the team. Notably, Dr. Beske was President of Aragen Biosciences, Inc. where he led a multidisciplinary team to bring value-added services to the biologics industry. Most recently, he served as the CEO of Alloy Therapeutics, Inc. a start up antibody discovery platform company. Dr. Beske received a BS in Physiology and Biochemistry from CSULB and a PhD in Cell Biology from UC San Francisco.


Message Presenter

Who Should Attend?

This webinar will appeal to professionals in the following fields/job functions:

  • Antibody discovery and engineering
  • Cell line development
  • Process development
  • CMC
  • Emerging biopharma
    • New companies bringing an asset to IND for the first time
    • Preclinical and clinical-stage biotechs

What You Will Learn

Attendees will learn about:

  • SBC-based platforms, which represent a paradigm shift for start-up biotech companies and enable them to reduce the cost/time cycle of early development
  • Better alignment between biotechs and service providers (CROs and CDMOs) to bridge the translation from preclinical to clinical development more effectively

Xtalks Partner


ATUM is a fully integrated biotechnology industry leader who over the last two decades has served our clients by delivering the highest quality Gene Design & Gene Synthesis, Protein Production, Protein Engineering, Cell Line development, using our own proprietary Leap-In Transposase® and Master Cell Banking. With a state-of-the-art machine learning platform, we take you from sequence to MCB with a click of the button. ATUM provides a continual commitment to innovation where our services are built on bioengineered solutions to bring speed to market, supporting you from pre-clinical through IND. Contact us today for more information at

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account